Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Mattsson

Showing results (181-190 of 258) with videos related to

Pageof 26
Sort By:
European Journal of Haematology|December 14, 2021
Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donorsIgor Novitzky-Basso, Mats Remberger, Carol Chen, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|June 16, 2022
Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantationShruti Prem, Mats Remberger, Ahmad Alotaibi, et al.
European Journal of Haematology|July 18, 2023
Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remissionTommy Alfaro Moya, Jonas Mattsson, Mats Remberger, et al.
Bone Marrow Transplantation|June 26, 2023
Propensity score matching analysis comparing the efficacy of Ruxolitinib to historical controls in second-line or beyond treatment for chronic GvHD after steroid failureIgor Novitzky-Basso, Swe Mar Linn, Jennifer White, et al.
Transplantation and Cellular Therapy|March 10, 2024
Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell TransplantationAyman Sayyed, Carol Chen, Armin Gerbitz, et al.
Transplantation and Cellular Therapy|January 22, 2026
Frailty as a prognostic factor in younger adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationSergio Rodriguez-Rodriguez, Maria Queralt Salas, Nihar Desai, et al.
British Journal of Haematology|February 26, 2026
Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemiaNihar Desai, Mohammed Althobaiti, Carol Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 19, 2020
Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous LeukemiaMaria Queralt Salas, Shiyi Chen, Wilson Lam, et al.
Leukemia & Lymphoma|August 26, 2021
Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infectionsMaria Queralt Salas, Eshetu G Atenafu, Arjun Datt Law, et al.
European Journal of Haematology|October 13, 2020
Prolactin, a potential biomarker for chronic GVHD activityMaria Queralt Salas, Shereen Ezzat, Wilson Lam, et al.
Pageof 26

Showing results (181-190 of 258) with videos related to

Sort By:
Pageof 26
European Journal of Haematology|December 14, 2021
Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donorsIgor Novitzky-Basso, Mats Remberger, Carol Chen, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|June 16, 2022
Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantationShruti Prem, Mats Remberger, Ahmad Alotaibi, et al.
European Journal of Haematology|July 18, 2023
Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remissionTommy Alfaro Moya, Jonas Mattsson, Mats Remberger, et al.
Bone Marrow Transplantation|June 26, 2023
Propensity score matching analysis comparing the efficacy of Ruxolitinib to historical controls in second-line or beyond treatment for chronic GvHD after steroid failureIgor Novitzky-Basso, Swe Mar Linn, Jennifer White, et al.
Transplantation and Cellular Therapy|March 10, 2024
Pretransplant Blinatumomab Improves Outcomes in B Cell Acute Lymphoblastic Leukemia Patients Who Undergo Allogeneic Hematopoietic Cell TransplantationAyman Sayyed, Carol Chen, Armin Gerbitz, et al.
Transplantation and Cellular Therapy|January 22, 2026
Frailty as a prognostic factor in younger adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationSergio Rodriguez-Rodriguez, Maria Queralt Salas, Nihar Desai, et al.
British Journal of Haematology|February 26, 2026
Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemiaNihar Desai, Mohammed Althobaiti, Carol Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 19, 2020
Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous LeukemiaMaria Queralt Salas, Shiyi Chen, Wilson Lam, et al.
Leukemia & Lymphoma|August 26, 2021
Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infectionsMaria Queralt Salas, Eshetu G Atenafu, Arjun Datt Law, et al.
European Journal of Haematology|October 13, 2020
Prolactin, a potential biomarker for chronic GVHD activityMaria Queralt Salas, Shereen Ezzat, Wilson Lam, et al.
Pageof 26